-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nivolumab, a fully human antibody drug that can recognize programmed cell death receptor-1 (PD-1), has been approved for the treatment of non-small cell lung cancer ( NSCLC ), malignant melanoma, renal cell carcinoma, Classic Hodgkin’s lymphoma , head and neck cancer, malignant mesothelioma, esophageal cancer, colorectal cancer with highly unstable microsatellites andGastric cancer (GC)
.
However, there is no large amount of real data on the effectiveness and safety of immunotherapy in gastric cancer
.
Although some tumors can grow rapidly after immunotherapy, the specific patient ratio and survival prognosis are still unclear
immunity
This study is a multi-center, prospective observational study designed to evaluate the clinical prognosis of patients with gastric cancer treated with nivolumab, including survival time, safety and tumor behavior
.
The primary endpoint is overall survival (OS), and secondary endpoints include response rate (RR), disease control rate (DCR), progression-free survival (PFS) and tumor growth rate (TGR) at the first assessment, as well as safety
Multivariate analysis of PFS and OS
Multivariate analysis of PFS and OSA total of 501 patients were recruited, of which 487 were evaluable (median age 70 years old, 71% male, 42%/44%/14% and 21% of patients with a performance status of 0/1/2) HER2-pos, 42% have ascites)
.
The median OS was 5.
The median OS was 5.
Median overall survival of HPD and non-HPD patients
Median overall survival of HPD and non-HPD patientsAmong 282 patients with detectable lesions, the disease control rate was 39.
4%, and the remission rate was 14.
2% (95% CI 10.
3-18.
8)
.
Among 219 patients who can be assessed for tumor growth rate, 20.
Among 282 patients with detectable lesions, the disease control rate was 39.
Original source:
Original source:Takahashi, Y.
Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08) in this message